https://adalimumabinhibitor.co....m/guideline-concorda
This analysis discusses the literature regarding the B cellular surface markers analysed by flow cytometry in clients treated with rituximab. A panel of biomarkers of response to treatment to monitor by flow cytometry is also recommended. B cellular phenotyping is useful to anticipate medical relapses after rituximab therapy. The proposed panel of biomarkers includes CD38++CD24++IgD+/- immature B cells and IgD-CD38+/- memory B cells. In responders, Th1/Th2 balance an
Aimer
Commentaire
Partagez
